<?xml version="1.0" encoding="UTF-8"?>
<p>Since the approval of telaprevir and boceprevir in 2011 with SVR rates of 65% to 75%, the landscape of antiviral therapy for chronic HCV has expanded, with development of well‐tolerated, pan‐genotypic, all‐oral, DAA therapies available to a variety of special populations (Table 
 <xref rid="hep41480-tbl-0002" ref-type="table">2</xref>). Additionally, recent updates to the AASLD recommendations have developed a simplified approach to treat chronic HCV, recommending glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks in all patients with HCV who are treatment‐naïve, noncirrhotic, with normal renal function and without comorbid infections.
 <xref rid="hep41480-bib-0021" ref-type="ref">21</xref>
</p>
